Fresenius Kabi Completes Acquisition of Ivenix
Expands infusion therapy portfolio and creates opportunities for innovation to help drive efficiencies and advance patient care
May 4, 2022
LAKE ZURICH, Ill., May 4, 2022 – Following the announced closing of the acquisition of Ivenix and its advanced infusion pump technology, Fresenius Kabi now offers health care professionals in the United States a broad and expanding portfolio of advanced infusion pumps and solutions to meet needs across the continuum of care.
Fresenius Kabi is the leading provider of IV pumps and solutions in Europe. The company is now investing to establish leadership in the U.S. as part of the company’s Vision 2026 growth strategy. In addition to the acquisition of Ivenix products, the company is in the final stages of completing a highly automated manufacturing center for IV solutions in Wilson, North Carolina – the most advanced plant of its kind in the U.S.
“Now more than ever, it is critical that we equip and empower clinicians with the safest, most effective, and connected infusion equipment possible,” said Pete Allen, senior vice president, Nutrition and Infusion Therapy, Fresenius Kabi USA. “With the Ivenix Infusion System, we expand the combined infusion therapy portfolio, accelerate innovation and enhance infusion capabilities resulting in improved medication safety and operational efficiency.”
Current IV pumps available from other U.S. manufacturers are built on decades-old technology and have experienced a range of safety issues, cyber vulnerabilities and recalls. Today’s digitally-enabled patient care needs new technology that is a better fit for the purpose.
The Ivenix Infusion System includes a large-volume infusion pump with administration sets, infusion management tools and analytics to inform care and advance efficiency. Ivenix technology is centered around the patient and clinician and is designed to reduce infusion-related errors and drive down the total cost of ownership. The Ivenix Infusion system is U.S. Food and Drug Administration (FDA) cleared and was launched in 2021. To learn more about the Ivenix Infusion System, visit www.ivenix.com.
“With the global leadership of Fresenius Kabi, we look forward to bringing far-reaching benefits to many health care organizations that seek best-in-class infusion solutions to meet their needs in safety, interoperability and efficiency,” said Jesse Ambrosina of Ivenix, who is now Senior Vice President, Infusion Nutrition Systems North America for Fresenius Kabi.
Fresenius Kabi has rapidly expanded its infusion therapy portfolio in the U.S. with a succession of FDA approvals for multiple IV solutions in anticipation of the company qualifying its North Carolina manufacturing site to supply U.S. customers with IV solutions.
Fresenius Kabi has a global infusion device portfolio and more than 35 years of infusion technology expertise, including more than 1.2 million infusion device installations to date worldwide. In March, Fresenius Kabi announced the newest addition to that portfolio when the Agilia® Connect Infusion System received 510(k) regulatory clearance from the FDA for its wireless Agilia® Connect Infusion System which includes the Agilia® Volumetric Pump and the Agilia® Syringe Pump with Vigilant® Software Suite-Vigilant® Master Med technology.
About Fresenius Kabi
Fresenius Kabi (www.fresenius-kabi.com/us) is a global health care company that specializes in medicines and medical technologies for infusion, transfusion, and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. To learn about U.S. career opportunities at Fresenius Kabi, visit us at www.fresenius-kabi.com/us/join-us.